Nuvalent Submits FDA New Drug Application for Neladalkib in ALK-positive Lung Cancer

Nuvalent, Inc. (NUVL) has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug, neladalkib. The drug is designed to treat patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have previously undergone treatment with tyrosine kinase inhibitors (TKIs). This regulatory submission is supported by clinical data from the global ALKOVE-1 Phase 1/2 trial, which evaluated the efficacy and safety of the ALK-selective inhibitor. The move marks a critical milestone for the clinical-stage biotech company as it transitions toward potential commercialization. Market analysts view this development as a significant de-risking event for Nuvalent's lead candidate. If approved, neladalkib could provide a new therapeutic option for a patient population with high unmet medical needs.